Norge -
norsk -
Statens legemiddelverk
bactrim 400 mg / 80 mg
eumedica pharmaceuticals gmbh - sulfametoksazol / trimetoprim - tablett - 400 mg / 80 mg
Norge -
norsk -
Statens legemiddelverk
amiodaron hameln 50 mg/ ml
hameln pharma gmbh - amiodaronhydroklorid - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 50 mg/ ml
Norge -
norsk -
Statens legemiddelverk
ezetimib aristo 10 mg
aristo pharma gmbh - ezetimib - tablett - 10 mg
Norge -
norsk -
Statens legemiddelverk
ezetimib/simvastatin glenmark 10 mg / 20 mg
glenmark arzneimittel gmbh - ezetimib / simvastatin - tablett - 10 mg / 20 mg
Norge -
norsk -
Statens legemiddelverk
ezetimib/simvastatin glenmark 10 mg / 40 mg
glenmark arzneimittel gmbh - ezetimib / simvastatin - tablett - 10 mg / 40 mg
Norge -
norsk -
Statens legemiddelverk
dronedaron aristo 400 mg
aristo pharma gmbh - dronedaronhydroklorid - tablett, filmdrasjert - 400 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - immunsuppressive - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
heplisav b
dynavax gmbh - hepatitt b overflate antigen - hepatitt b - vaksiner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.